Credit score: CC0 Public Area
New analysis exhibits that the diabetes/weight problems medicine tirzepatide may cause clinically significant enhancements in blood sugar management and weight reduction in kids and adolescents with kind 2 diabetes aged 10–17 years whose diabetes and weight are inadequately managed with an current therapy routine of metformin, insulin, or each.
The examine (the SURPASS-PEDS trial), by Dr. Tamara Hannon, Division of Pediatric Endocrinology and Diabetology, Indiana College College of Drugs, was offered on the Annual Assembly of the European Affiliation for the Research of Diabetes (EASD) in Vienna, Austria (15–19 September) and revealed in The Lancet.
Youth-onset kind 2 diabetes (YT2D) is a quickly progressing illness with rising incidence in recent times, primarily pushed by the rise within the international prevalence of weight problems. The general incidence of kind 2 diabetes in kids and adolescents within the U.S. has almost doubled throughout 15 years, going from 9.0 to 17.9 instances per 100,000 individuals per 12 months between 2002–03 and 2017–18.
There are restricted therapy choices to enhance blood sugar (glycemic) management in YT2D. Current therapeutics have typically demonstrated decrease glycemic efficacy in YT2D in comparison with adults with T2D, with out clinically significant influence on weight as measured by physique mass index (BMI).
Tirzepatide is a as soon as weekly GIP/GLP-1 receptor agonist authorised for the therapy of adults with T2D, weight problems, and obstructive sleep apnea (within the U.S., and authorised for treating T2D and weight problems in lots of different international locations). The security and efficacy of tirzepatide in YT2D is but to be reported.
On this Part III trial, 99 younger individuals aged 10–17 years with YT2D with insufficient glycemic management with metformin, basal insulin, or each, had been randomized in a 1:1:1 ratio to obtain blinded therapy with tirzepatide (5 mg or 10 mg) or placebo (PBO) as soon as weekly for 30 weeks adopted by a 22-week open-label extension.
The first intention was to show superiority of tirzepatide (wanting on the pooled outcomes of each doses mixed) versus placebo for change in glycated hemoglobin (HbA1c—a measure of blood sugar management) at 30 weeks. Analyses included all individuals who obtained a minimum of one dose of examine drug, excluding information after discontinuation of examine drug or initiation of glycemic rescue remedy (that is when an individual’s blood sugar is so excessive they want intensive medical therapy to get better).
At baseline, the imply age was 14.7 years, imply length of diabetes was 2.4 years, and individuals had been handled with metformin (68.7%), basal insulin (8.1%), or each (23.2%).
At 30 weeks, tirzepatide was superior to placebo for enhancing HbA1c, fasting serum glucose, BMI, and incidence of HbA1c of 6.5% or much less (beneath the vary for diabetes) and 5.7% of much less (beneath the vary for prediabetes). Within the placebo group, these indicators barely modified or didn’t change throughout the 30 weeks of the examine.
At the beginning of the examine, all the kids had HbA1c above 6.5%, classifying them as having kind 2 diabetes. At 30 weeks, the pooled tirzepatide outcomes present that greater than three-quarters (79%) of kids taking tirzepatide had an HbA1c of lower than 6.5%, and greater than half (53%) had an HbA1c of lower than 5.7%, in comparison with 29% and 14% respectively for these taking placebo
And whereas imply BMI fell simply 0.4 factors throughout the 30 weeks within the placebo group, from 34.7 to 34.3 kg/m2, within the pooled tirzepatide group, imply BMI fell 9.3 items from 35.6 to 26.3 kg/m2. Fasting glucose ranges fell by round six instances extra within the pooled tirzepatide group (2.46 items) than the placebo group (0.44 items).
The estimated imply therapy distinction (between tirzepatide pooled outcomes and placebo) for change from baseline had been: HbA1c -24.9 mmol/mol (-2.3%), FSG -2.0 mmol/L (-36.3 mg/dL) and BMI -8.9%. At 52 weeks, the estimated imply change from baseline in HbA1c was -24.2 mmol/mol (-2.21%) and the share change in BMI from baseline was -12.0%, for TZP pooled.
The most typical hostile occasions on tirzepatide had been gastrointestinal, delicate to average in severity, occurred largely throughout dose escalation, and usually decreased over time (according to trials in adults). Therapy discontinuation on account of hostile occasions occurred in 6.3% of individuals in tirzepatide 5 mg and 0% in tirzepatide 10 mg and placebo.
No extreme hypoglycemia episodes had been reported through the examine. Glycemic rescue remedy was initiated by 18% of individuals within the placebo group and nil individuals within the tirzepatide pooled group.
The authors conclude, “Tirzepatide demonstrated significant and clinically meaningful improvements in blood sugar control and BMI in youth with type 2 diabetes. The impact on blood sugar control was sustained over the one-year trial period and improvements in BMI continued through the year and did not plateau.”
“Tirzepatide is the first drug used for type 2 diabetes in this age group that has shown sustained clinically meaningful BMI-lowering effects …These results support tirzepatide as a potential safe and efficacious treatment option for youth-onset type 2 diabetes.”
Extra data:
Efficacy and security of tirzepatide in kids and adolescents with kind 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, section 3 trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)01774-X
Offered by
European Affiliation for the Research of Diabetes
Quotation:
Research: Tirzepatide improves blood sugar management in kids with poorly managed kind 2 diabetes (2025, September 18)
retrieved 18 September 2025
from https://medicalxpress.com/information/2025-09-tirzepatide-blood-sugar-children-poorly.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
